This article is over a month old and may contain outdated advice from the authorities regarding coronary heart disease.
Stay up to date in NRK’s overview, or through FHIs nettsider.
–
A panel of medical advisers voted on Tuesday to recommend approval of Pfizer’s covid-19 vaccine to younger children. It reports the news agency AFP.
The panel is composed of experts in the FDA (Food and Drug Administration).
A study that has recently been made public, shows that the vaccine is 90.7 percent effective against coronavirus in this age group, writes NTB.
It opens the door for 28 million American children to receive the first dose of Pfizer in a short time, probably from the first week of November.
Have start assessment
– It is quite clear to me that the benefits outweigh the risks when I hear about children who are admitted to the intensive care unit, who have long-term ailments after Covid and children who die.
That’s what Amanda Cohn from the Center for Disease Control and Prevention (CDC) says.
She is the CDC’s representative in this expert group, and it is the CDC that finally approves this.
17 in the panel voted to approve Pfizer for children, one abstained from voting.
The European Medicines Agency (EMA) has also started its assessment of the application from BioNTech / Pfizer’s vaccine for children aged 5 to 11 years.
They report it themselves their homepages October 18th.
– We expect to have a clear conclusion on this in a couple of months, writes EMA.
Will not approve before the EU
It is the European Commission that ultimately decides whether this age group can receive this vaccine.
Camilla Stoltenberg is director of the National Institute of Public Health (NIPH). She told NRK on Tuesday night that they are closely following what is happening in the USA and the EU.
– Norway will not approve or recommend vaccines for children until the European Medicines Agency has looked at this and possibly given a recommendation, says Stoltenberg.
–
